Indevus Pharmaceuticals — Valera Pharmaceuticals — Merger or Acquisition (December 2006)
26 slides from Indevus Pharmaceuticals's merger presentation, Dec 12, 2006
Slide 1: Acquisition of Valera Pharmaceuticals
Exhibit 99.1 Acquisition of Valera Pharmaceuticals December 12, 2006
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. Such statements include, but are not limited to, the timing of completion of the tran
Slide 3: Indevus 2006 – A Year of Milestone Achievement
Indevus 2006 – A Year of Milestone Achievement • Acquired U.S. rights to DELATESTRYL® • Completed enrollment of NEBIDO® Phase III PK study • Announced positive results of pagoclone stuttering trial • Announced positive results of SANCTURA XR™ Phase III studies • Completed $35.0 million secondary off
Slide 4: Strategic Rationale
Strategic Rationale Acquisition creates an emerging leader in urology and men’s health • Perfect fit with the Indevus corporate strategy of building a world class urology and men’s health franchise • Upon closing, the combined Company will have 3 marketed products (one from Valera) and anticipates 5
Slide 5: Indevus + Valera – Product Pipeline
Indevus + Valera – Product Pipeline Building a Focused Portfolio of Products CORE THERAPEUTIC AREAS Phase I Phase II Phase III NDA Market SANCTURA® Overactive bladder VANTAS ® Prostate Cancer DELATESTRYL ® Hypogonadism VALSTAR ® Bladder Cancer Central Precocious SUPPRELIN® -LA Puberty SANCTURA XR ™
Slide 6: Indevus + Valera – Product Pipeline
Indevus + Valera – Product Pipeline Partnered & Partnerable Products OTHER THERAPEUTIC AREAS Preclinical Phase I Phase II Phase III Market Pagoclone Stuttering IP 751 Anti-inflammatory Disorders Naltrexone Implant Drug Addiction Hydron Implant Tech Other Uses Sarafem PMDD Licensed to Eli Lilly/Galen
Slide 7: Transaction Overview
Transaction Overview • Stock for Stock purchase of Valera Pharmaceuticals (VLRX) • $7.75 per share of Valera common stock with 10% collar Maximum exchange ratio: 1.1766 Minimum exchange ratio: 0.9626 • Deal Value ~ $120 Million + contingent payments • Contingent Payments in Indevus stock: $1.00/shar
Slide 8: Indevus Product Portfolio: SANCTURA XR
Indevus Product Portfolio SANCTURA XR™ - Overactive Bladder Current Profile of SANCTURA® Only quaternary ammonium on the market Low CNS side-effects No clinically relevant metabolic drug-drug interactions Excreted largely unchanged in the urine Rapid onset of action PLUS Once-a-day dosing Lower anti
Slide 9: Indevus Product Portfolio: Co-Promotion Financial Terms with Esprit Pharma
Indevus Product Portfolio Co-Promotion Financial Terms with Esprit Pharma Up Front and Approval Milestone $150M Phase III Initiation Milestone $ 10M NDA Submission $ 10M Future Milestones: Approval $35M Commercialization (2013) $20M Royalty Rates Guaranteed Minimum Royalties 15% $ 0 - $ 75M 7/1/05-6
Slide 10: Indevus Product Portfolio: NEBIDO - Hypogonadism
Indevus Product Portfolio NEBIDO® - Hypogonadism • Novel, long-acting preparation of testosterone undecanoate • First and ONLY 3-month injection • Approved in over 80 countries • Phase III pharmacokinetic study complete – Q2 2007 • Anticipated NDA submission – Summer 2007 • Highly differentiable fro
Slide 11: Indevus Product Portfolio: Pagoclone - Persistent Stuttering
Indevus Product Portfolio Pagoclone - Persistent Stuttering • Over 3 million patients in the U.S. with persistent stuttering • Novel, selective GABA-A receptor agonist • Complete toxicology, pharmacology and manufacturing packages for NDA with more than 1,000 patients studied in previous anxiety tri
Slide 12: Indevus Product Portfolio: PRO 2000
Indevus Product Portfolio PRO 2000 - Prevention of Sexual Transmission of HIV • Topical vaginal microbicide blocks pathogen entry into susceptible cells • Active against a wide range of HIV isolates, chlamydia, herpes and gonorrhea • Significant interest in female-controlled option • >$100M in desig
Slide 13: Valera Product Portfolio: VANTAS
Valera Product Portfolio VANTAS ® (histrelin implant) - Advanced Prostate Cancer • U.S. launch - November 2004 • Soft, flexible implant utilizing Hydron Implant Technology • 12-month implant to deliver histrelin (most potent LHRH agonist) for the treatment of advanced prostate cancer Limits need for
Slide 14: VANTAS Co-Promotion Financial Terms with Indevus
Valera Product Portfolio VANTAS ® Co-Promotion Financial Terms with Indevus • Separate agreement to co-promote VANTAS ® • Indevus sales force to initiate co-promotion activities in January 2007 Indevus ~ 85 reps Valera ~ 25 reps • 2-year term • Royalty rates: 13.5% of VANTAS ® sales up to a baseline
Slide 15: Valera Product Portfolio: SUPPRELIN-LA - Central Precocious Puberty
Valera Product Portfolio SUPPRELIN®-LA - Central Precocious Puberty • 12-month specifically formulated implant to deliver histrelin for the treatment of central precocious puberty (CPP) • Provides consistent, reliable suppression for a 12- month period • FDA Granted Orphan Drug Status in November 20
Slide 16: SUPPRELIN-LA - Central Precocious Puberty
Valera Product Portfolio SUPPRELIN®-LA - Central Precocious Puberty • CPP is the early onset of puberty in young children • Incidence: 1 in every 5,000 – 10,000 children More common in female children Patient age: typically under 9 years; as young as 4 years or less Duration of therapy: 3 to 5 years
Slide 17: SUPPRELIN-LA - Market Opportunity
Valera Product Portfolio SUPPRELIN®-LA - Market Opportunity Offer parents a choice This Or 13 - 17 injections per year for 3 to 5 years SUPPRELIN®-LA Sample Responses From Surveyed Ped Endos • Implant conceptually attractive - easier on families; less traumatic for kids • Steady 1-year hormonal supp
Slide 18: Valera Product Portfolio: VALSTAR - Bladder Cancer
Valera Product Portfolio VALSTAR ® (valrubicin) - Bladder Cancer • Anthracycline derivative of Doxorubicin solution for bladder instillation • Current approved usage 29,000 BCG refractory patients per year (AUA est.) • 15,000 – not candidates for bladder removal • Valstar ® is the only approved prod
Slide 19: Valera Product Portfolio: Octreotide Implant - Acromegaly
Valera Product Portfolio Octreotide Implant - Acromegaly • 6 month octreotide (somatostatin analog) implant to treat acromegaly • Acromegaly: a chronic hormonal disorder Excessive growth hormone & abnormal physical features Higher incidence of diabetes & cardiovascular disease • Current therapy: San
Slide 20: Octreotide Implant - Acromegaly
Valera Product Portfolio Octreotide Implant - Acromegaly • Approximately 1,000 new acromegaly patients per year Treated by endocrinologists • Completed Phase I/II study demonstrating significant suppression of growth hormone and IGF-1 levels for 6 months • Commencing Phase II pharmacokinetic study i
Slide 21: Valera Product Portfolio: Biodegradable Ureteral Stent
Valera Product Portfolio Biodegradable Ureteral Stent • Presently, conventional non-biodegradable stents are inserted into the ureter to allow urine to drain when the flow of urine may be obstructed Approximately 1.2 million procedures per year for the removal of kidney stones in U.S. Estimated 800,
Slide 22: Financial Highlights
Financial Highlights Valera 14.9 million shares outstanding $19.9 million in LTM revenues $11.0 million in LTM Net Loss $18.9 million in Cash (9/30/06) No Debt Combined Company – pro forma $70.4 million in LTM revenues $95.0 million in Cash (9/30/06) Acquisition expected to be accretive within 2 yea
Slide 23: Integration Plan
Integration Plan • Expected Closing – on or around April 30, 2007 Subject to Indevus and Valera shareholder approval HSR clearance Other customary conditions of merger agreement • Indevus President/COO & Indevus EVP/Chief Business Officer to lead integration planning • Cross-functional integration t
Slide 24: 2007 Milestones
2007 Milestones Begin VANTAS ® co-promotion Pagoclone Phase III initiation SUPPRELIN®-LA approval and launch VALSTAR ® supplemental NDA submission NEBIDO® NDA submission SANCTURA XR™ approval and launch Octreotide Implant Phase III initiation Biodegradable Ureteral Stent 510k submission
Slide 25: Additional Information and Where to Find It
Additional Information and Where to Find It In connection with the merger between Indevus and Valera, Indevus intends to file with the SEC a registration statement on Form S-4, containing a joint proxy statement/prospectus and other relevant materials. The final joint proxy statement/prospectus will
Slide 26: Valera Pharmaceuticals
VALERA Pharmaceuticals
Valera Pharmaceuticals — Merger or Acquisition (December 2006) on 6ix